Overview of Emetrex

What is Emetrex? Quick Facts

Property	Description
Active Ingredient	Cyclizine
Form	Tablet and Injection (solution)
Pharmacological Class	Antiemetic agent, Histamine H1 receptor antagonist
General Purpose	Relief of nausea, vomiting, and dizziness
Origin	Synthetic chemical compound

What Type of Medicine is Emetrex and What is its Composition?

Emetrex is a pharmaceutical preparation whose primary role is to act as an antiemetic agent, specifically formulated to help relieve nausea, vomiting, and dizziness. This medication contains the active ingredient Cyclizine, a substance defined as a synthetic chemical compound that belongs to the piperazine class. It is classified as a Histamine H1 receptor antagonist, a designation relating to its primary mechanism of action. This classification means the medication works by blocking certain histamine receptors in the central nervous system. As a single-ingredient product, Emetrex provides a focused treatment approach, utilizing only Cyclizine as the therapeutically active component.

What is the General Purpose of Cyclizine?

The general purpose of Cyclizine is to manage and counter the uncomfortable symptoms of nausea, vomiting, and dizziness. This makes it a clinical option for situations where balance disruption or chemical triggers cause distress. The drug's mechanism involves the suppression of labyrinthine excitability (calming the balance signals from the inner ear) and the inhibition of the brain's Chemoreceptor Trigger Zone (CTZ). By stabilizing these signals and blocking the chemical triggers that incite the vomiting reflex, Cyclizine provides generalized relief and control over these distressing symptoms.

Is Emetrex Available as a Tablet or an Injection?

Emetrex is supplied in two primary dosage forms: an oral tablet and a solution intended for parenteral administration (an injection). The oral tablet typically contains the salt form Cyclizine hydrochloride, which is administered by mouth. The solution for injection contains Cyclizine lactate for intramuscular or intravenous use. This availability in both solid and injectable formats ensures flexibility for administration in various settings, including acute situations where oral intake is compromised.

Regulatory References

NIH MedlinePlus

What side effects are possible with Emetrex ?

The safety profile of Emetrex (Cyclizine) is categorized by regulatory authorities into frequency tiers and System-Organ Classes (SOCs). This classification is based on real-world clinical data and documentation from official sources.

Adverse Reactions and Frequency Classification

Frequency	System-Organ Class	Officially Documented Effects
Common	Nervous System, Gastrointestinal	Drowsiness, Sedation, Dry mouth, Headache
Uncommon	Nervous System, Eye Disorders	Dizziness, Blurred vision
Rare	Hepatobiliary, Cardiac & Vascular, Immune	Hepatic dysfunction (e.g., hepatitis), Hypotension, Tachycardia, Anaphylactic reactions

Certain effects, such as drowsiness and sedation, are noted to be more pronounced at the beginning of treatment.

Serious Adverse Reactions and Safety Constraints

Serious reactions, though rare, include anaphylactic reactions (severe allergic response) and hepatic dysfunction. A safety pattern noted in regulatory documents is the risk of paradoxical central nervous system (CNS) stimulation (e.g., excitement, restlessness), particularly in the pediatric and older adult populations.

Due to its established anticholinergic properties, Cyclizine is contraindicated in individuals with known hypersensitivity to the drug. Caution is formally advised in patients with conditions that may be exacerbated by anticholinergic activity, such as angle-closure glaucoma, conditions causing urinary retention, and pyloric obstruction. Furthermore, the concurrent use of Cyclizine with other CNS depressants, including alcohol, may result in additive depressant effects leading to enhanced sedation.

Overdose and Emergency Response

Overdose and When to Seek Help

The officially documented profile for Emetrex (Cyclizine) overdose describes a serious clinical picture resulting from pronounced central nervous system (CNS) and peripheral anticholinergic effects. Documented manifestations of acute toxicity include signs such as drowsiness, dizziness, incoordination, disorientation, impaired judgment, hallucinations, blurred vision, tachycardia (rapid heart rate), and urinary retention. Overdose can escalate to severe and life-threatening systemic outcomes, including convulsions, hyperpyrexia (severe elevation of body temperature), respiratory depression, apnoea, and cardiac arrhythmias.

Regulators mandate that immediate medical attention must be sought if overdosage is suspected or confirmed. Urgent professional care is required for any severe manifestations, such as seizures or difficulty breathing. The management procedures officially defined in regulatory labeling are symptomatic and supportive, as no specific antidote is documented for Cyclizine toxicity. These procedures may include supportive measures for respiration and circulation, as well as the use of parenteral anticonvulsant therapy to control seizures. A specific population note is included in official documents stating that younger children are more susceptible to convulsions, a risk that is documented relative to specific ingested dose levels.

Therapeutic Uses of Emetrex

What Emetrex Treats: Main Uses and Benefits

Emetrex (Cyclizine) is an antiemetic agent primarily used for managing distressing symptoms related to nausea, vomiting, and dizziness. The therapeutic scope of the medication includes three key areas of symptomatic management.

The medication is commonly used to help ease pronounced symptoms in conditions presenting with acute episodes, including sickness from motion or travel, vertigo, and conditions associated with systemic imbalance such as Ménière's disease. It is also relevant when supportive symptom management is appropriate in clinical settings, such as for nausea following general anesthesia (PONV), or sickness linked to therapeutic agents like opioid analgesics and specific types of radiotherapy.

By addressing these symptom clusters, Emetrex supports general well-being during symptomatic phases and contributes to improved comfort.

“This application may assist with easing the overall symptom load during periods of heightened discomfort.”

Quick Fact: Relief for Nausea, Vomiting, and Dizziness

Managing Motion Sickness and Travel-Related Nausea

Emetrex is commonly used to address motion-triggered symptoms and is applied in addressing both prevention and treatment of sickness arising from movement. It may assist with easing the pronounced symptoms of nausea, vomiting, and dizziness during travel, which contributes to improved comfort during periods of heightened symptoms.

Symptomatic Relief for Vertigo and Vestibular Disorders

The medication offers symptomatic relief for conditions where functional stability becomes affected. It is relevant when symptoms cluster into disruptive manifestations of vertigo and dizziness, particularly in conditions characterized by periods of heightened symptoms associated with unsteadiness (e.g., acute episodes of Ménière's disease).

Controlling Acute Nausea in Clinical Settings

Emetrex is commonly used in clinical and hospital settings when supportive symptom management is appropriate during phases of increased distress or discomfort. This includes addressing symptomatic discomfort following general anesthesia or nausea linked to therapeutic agents, which contributes to easing the overall symptom load of these disruptive manifestations.

Eligibility and Restrictions for Use

Who Can and Cannot Use Emetrex?

Population eligibility for Emetrex (Cyclizine) is determined by official regulatory labeling, which establishes specific contraindications and conditional restrictions.

Contraindicated Populations

Use of Emetrex is formally contraindicated and must be avoided in patients with known hypersensitivity to Cyclizine, porphyria, or acute alcohol intoxication. Oral tablets containing lactose are also contraindicated in individuals with rare hereditary problems, such as galactose intolerance.

Age and Physiological Restrictions

Population Group	Regulatory Status
Children under 6 years	Not recommended for use (oral tablets).
Pregnancy	Use is not advised due to insufficient definitive data.
Breastfeeding	Use is not recommended as Cyclizine is excreted in human milk.

Conditional Use

The medicine is classified for use with caution in populations with specific pre-existing conditions. These include glaucoma, conditions leading to urinary retention, epilepsy, hypertension, severe heart failure, or obstructive gastrointestinal disease. Patients with hepatic impairment also require caution and monitoring.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory profile for Emetrex (Cyclizine) is primarily defined by documented pharmacodynamic interactions, which result from additive effects with certain substance classes, rather than pharmacokinetic mechanisms like enzyme alteration.

Emetrex may have additive central nervous system (CNS) depressant effects when co-administered with alcohol and other CNS depressants, including hypnotics, tranquillisers, anaesthetics, antipsychotics, and barbiturates. This additive effect is also noted to enhance the sedating effect of medicines such as pethidine.

Co-administration with other anticholinergic drugs or antimuscarinic agents, such as atropine, certain tricyclic antidepressants, and MAOIs, may result in an additive antimuscarinic action. This is a documented interaction constraint that can lead to enhanced side effects.

Interaction-Related Restrictions

Classification	Constraint
Contraindicated Combination	Use of Cyclizine is contraindicated in the presence of acute alcohol intoxication as its anti-emetic effect may mask the symptoms of toxicity.
Effect-Masking Interaction	Cyclizine may mask the warning signs of damage caused by ototoxic drugs, such as aminoglycoside antibacterials, which requires clinical monitoring.
Effect-Modifying Interaction	It may also counteract the haemodynamic benefits officially associated with opioid analgesics.

No mandatory timing or separation requirements are documented in the official prescribing information for Cyclizine.

Mechanism of Action

How Emetrex Blocks Emetic Signals in the Brain

Emetrex acts as an antagonist by binding to and blocking Dopamine D2 receptors (D2 R) in the brain's Chemoreceptor Trigger Zone (CTZ). This mechanism suppresses the central signals that normally initiate the emetic reflex, leading to a reduction in the transmission of emetic stimuli.

Emetrex's Effect on Gastrointestinal Motility

The drug also exerts peripheral activity by acting as an agonist on Serotonin 5-HT4 receptors (5- HT4 R) located in the enteric nervous system of the stomach and intestines. This interaction enhances the release of acetylcholine, which in turn increases the frequency and coordination of smooth muscle contractions in the upper digestive tract. This cascade results in faster propulsive movement of material through the gastric system.

Dual Central and Peripheral Pathway Modulation

Emetrex's mechanism is defined by its simultaneous effect on both the central D2 R receptors and the peripheral 5- HT4 R pathways. This dual action modulates the central nervous system signals and the peripheral gastrointestinal function concurrently.

Dosage and Administration Information

How Emetrex is Used: Administration Guidelines

The administration of Emetrex occurs in two main forms to ensure flexible use in various clinical contexts. The medicine is available for oral administration as a 50 mg tablet and for parenteral administration via intramuscular (IM) and intravenous (IV) injection as a 50 mg/mL solution.

Dosing and Frequency

The standard dose for adults and children over 12 years is 50 mg. This dose may be repeated up to a maximum of three times daily, establishing a 24-hour ceiling for usage, with a minimum interval of eight hours between parenteral doses. The tablets may be taken with or without food. For the prevention of motion sickness, the first oral dose should be taken preemptively, specifically one to two hours before departure.

Procedural and Pediatric Rules

Specific dosing rules apply to pediatric populations. Children aged 6 to 12 years are administered a lower oral dose of 25 mg, which can be achieved by splitting the scored 50 mg tablet. The oral tablet is generally not recommended for children under six years of age. When administered intravenously, the solution must be injected slowly and may require dilution with standard fluids, such as Sodium Chloride 0.9% or Glucose 5%, to a concentration of 5 mg/mL. Furthermore, the injectable solution should not be mixed with other medicinal products unless compatibility is confirmed.

Recent Clinical Evidence

Research Evidence for Emetrex (Cyclizine)

Evidence for Managing Nausea After Surgery

The primary evidence for using Emetrex in surgical settings comes from randomized controlled trials (RCTs) and systematic reviews that have research examined its role in measuring symptoms following general anesthesia or surgery. Studies were primarily applied in trials assessing short-term or episodic symptom patterns in adults undergoing various types of surgery. Researchers studies monitored outcomes related to how symptoms changed, such as the frequency of vomiting and retching episodes, and changes in nausea intensity over a short-term, acute setting (24 to 48 hours).

While the evidence contributes to the broader evidence landscape for acute post-operative care, follow-up durations were limited. The research describes group patterns, not personal outcomes regarding how symptoms changed, and comparative data against all newer anti-nausea medications are limited.

Evidence for Motion Sickness and Travel-Related Symptoms

Emetrex was evaluated in research exploring symptoms triggered by movement, including studies related to travel. The research includes both prophylactic studies and trials where symptoms was observed in a study conducted during periods of increased symptom activity. The studies included healthy adults and specific groups of children (aged 6 and older).

These trials research examined outcomes related to systemic or functional imbalance, such as the ability to prevent the onset of nausea, vomiting, and dizziness. Some evidence is based on older studies, meaning the overall consistency of findings may vary across the research. There is limited information for long-term outcomes or how well the effect is maintained over continuous or repeated travel periods.

Studies on Vertigo and Vestibular Disorders

Emetrex was studied for its use in conditions characterized by fluctuating or episodic manifestations, such as acute episodes of vertigo. The evidence often comes from clinical practice summaries and smaller studies focusing on symptom management. Research studies explored outcomes capturing phases of heightened symptom activity, primarily focusing on the acute mitigation of vertigo, nausea, and vomiting during a flare-up. Research reports indicate that there is limited information for long-term outcomes or measures related to recurrence.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Emetrex (FAQ)

Q: How long does the anti-nausea effect of one dose of Emetrex typically last?

Official administration guidelines for Emetrex indicate a minimum interval of eight hours is required between injectable doses. This minimum time frame suggests that the drug is designed to provide relief for a period aligning with this frequency, although the exact duration of therapeutic effect is not universally specified.

Q: Is it true that Emetrex works best if it is taken before nausea begins?

According to official product information, taking Emetrex preemptively is explicitly recommended when using it for motion sickness. The guidelines advise taking the oral dose one to two hours before departure to help prevent symptoms from starting.

Q: Are there any specific warnings about using Emetrex in older adults?

Regulatory documents note a safety pattern in the older adult population regarding the potential for paradoxical central nervous system (CNS) stimulation. This means that instead of feeling drowsy, some older adults may exhibit excitement or restlessness. Use in this population is formally classified as requiring caution.

Q: Are there official guidelines regarding the use of Emetrex in children or teenagers?

Official guidelines specify different administration rules based on age. The oral tablet is not recommended for children younger than six years old. Specific rules exist for children aged 6 to 12 years, while individuals over 12 generally follow the adult dosing rules defined in the official label.

Q: Have there been any studies comparing Emetrex to similar prescription antiemetics?

Research summaries from regulatory bodies acknowledge that comparative data against all of the newer anti-nausea medications are limited. This indicates that while Emetrex has been examined in some comparative studies, a full body of comparative evidence against every modern drug in its class is not currently included in the official labeling.

Q: Are there known long-term side effects associated with prolonged Emetrex use?

Studies summarized in the official label note that follow-up durations were limited in many of the trials conducted. Consequently, regulatory documents indicate there is limited information available for long-term outcomes when Emetrex is used continuously or for very prolonged periods.

Q: Is Emetrex suitable for patients who have kidney or liver problems?

Official documents formally classify hepatic impairment (liver problems) as a condition requiring caution and monitoring. While the need for caution is specified for liver problems, explicit warnings related to kidney (renal) impairment are not universally detailed in the official prescribing information.

Q: Does Emetrex contain lactose, gluten, or other common allergens?

The official label confirms that Emetrex oral tablets contain lactose as an inactive ingredient. For this reason, the tablets are contraindicated in individuals diagnosed with rare hereditary problems like galactose intolerance. Information regarding gluten or other specific common allergens is not universally detailed.

Q: What research has been conducted on Emetrex use in patients with a history of seizures?

Official labeling lists epilepsy as a pre-existing condition requiring formal caution and monitoring. Although this warning exists, detailed summaries of clinical research specific to outcomes in patients with a history of seizures are not included in the standard prescribing information.

Q: Can Emetrex lose its effectiveness if it is exposed to heat or sunlight?

Regulatory storage mandates are in place to maintain the drug’s integrity and stability. Both the tablet and injection forms must be stored at a temperature not exceeding 25 C. Furthermore, the injectable solution must be kept in its outer carton to protect it from light until use.

Q: How quickly can a person expect Emetrex to start working after taking it?

While official labeling does not specify the exact time to onset for all uses, it does provide a clue regarding efficacy timing. For motion sickness prevention, the recommendation is to take the dose one to two hours before departure. This timing indicates the expected window for the medicine to become active in the body.

Q: Does Emetrex carry any special warnings from the FDA or other regulators (e.g., a Boxed Warning)?

Regulatory documentation includes systems for specific safety classifications, such as the potential requirement for a Black Box Warning or equivalent safety pattern. This type of warning is used by regulatory authorities to call attention to serious or life-threatening risks associated with the medicine.

Q: Why is Emetrex sometimes not recommended for people with Parkinson's disease?

Emetrex works in part by acting as a Dopamine D2 receptor antagonist, meaning it blocks dopamine signals in certain areas of the brain. Because disorders like Parkinson's disease involve the body's natural dopamine pathways, official documents suggest its use may be restricted due to the potential for issues related to the condition’s treatment.

Q: Why might a person feel an unusual sensation or urge to move while taking Emetrex?

The official label reports the potential for paradoxical central nervous system (CNS) stimulation in some individuals, particularly among children and older adults. This effect can manifest as unusual sensations such as excitement or restlessness and is part of the known safety profile reported in regulatory documents.

Q: Is Emetrex known to cause constipation or diarrhea?

While neither constipation nor diarrhea is explicitly listed as a common side effect, the drug's official profile notes related effects on the digestive system. Dry mouth is listed as a common anticholinergic effect, and obstructive gastrointestinal disease is listed in the official label as a condition that requires formal caution.

How should Emetrex be stored and disposed of?

Storage and Disposal of Emetrex (Cyclizine)

The official labeling mandates specific conditions for storing and disposing of Emetrex (Cyclizine) to maintain product integrity and safety.

Mandatory Storage Conditions

Formulation	Temperature Requirement	Protection Requirement
Tablet and Injection	Must be stored not exceeding 25 C	Keep out of the sight and reach of children.
Injection Solution	Store below 25 C	Must be kept in the outer carton to protect from light.

The medicine must not be used after the expiry date shown on the packaging. Any diluted injection solution must be used immediately, or if necessary, stored for no more than 24 hours under refrigeration.

Disposal Requirements

Used or expired Emetrex must not be thrown away via wastewater or household waste to comply with environmental regulations. Disposal should be done in accordance with local requirements, which usually involves returning the product to a pharmacist or local waste collection point.

Emetrex